Regulation (EU) 2026/1386 of the European Parliament and of the Council of 17 Jun... (32026R1386)
Regulation (EU) 2026/1386 of the European Parliament and of the Council of 17 Jun... (32026R1386)
REGULATION (EU) 2026/1386 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL
of 17 June 2026
on the screening of foreign investments in the Union and repealing Regulation (EU) 2019/452
CHAPTER 1
General provisions
Article 1
Subject matter and scope
Article 2
Definitions
CHAPTER 2
National screening mechanisms
Article 3
Establishment of screening mechanisms
Article 4
Minimum requirements
CHAPTER 3
The cooperation mechanism on foreign investments likely to negatively affect security or public order
Section I
Notification of foreign investments
Article 5
Notification of foreign investments
Article 6
Content and procedures for notification of foreign investments
Article 7
Specific rules applicable to multi-country transactions
Section II
Comments by Member States and opinions by the Commission
Article 8
Comments and opinions on notified foreign investments
Article 9
Intention to provide comments or issue an opinion
Article 10
Additional information
Article 11
Provision of comments and issuing of opinions
Article 12
Consideration of comments and opinions
Article 13
Comments and opinions on non-notified foreign investments
Section III
Requirements for ensuring effective cooperation
Article 14
General requirements
Article 15
Information requirements
Article 16
Information-gathering assistance
Article 17
Confidentiality of information exchanges in the cooperation mechanism
Article 18
Secure and encrypted system, online EU portal and secure database
CHAPTER 4
Foreign investments likely to negatively affect security or public order
Article 19
Determination of likely negative effect on security or public order
Article 20
Screening decisions on foreign investments likely to negatively affect security or public order
CHAPTER 5
Final and transitional provisions
Article 21
Group of experts on the screening of foreign investments into the Union
Article 22
International cooperation
Article 23
Public transparency requirements
Article 24
Annual reporting at Union level
Article 25
Processing of personal data
Article 26
Evaluation
Article 27
Delegated acts
Article 28
Exercise of the delegation
Article 29
Committee procedure
Article 30
Repeal of Regulation (EU) 2019/452 and transitional measures
Article 31
Entry into force and application
ANNEX I
TECHNOLOGY AREAS RELEVANT FOR THE COMMON MINIMUM SCOPE PURSUANT TO ARTICLE 4(15)
ANNEX II
PROJECTS OR PROGRAMMES OF UNION INTEREST
1.
Preparatory Action on Preparing the new EU GOVSATCOM programme
2.
Space Programme
3.
Union secure connectivity programme
4.
Horizon 2020, including research and development programmes pursuant to Article 185 TFEU, and joint undertakings or any other structure set up pursuant to Article 187 TFEU
5.
Horizon Europe, including research and development programmes pursuant to Article 185 TFEU, and joint undertakings or any other structure set up pursuant to Article 187 TFEU
6.
Euratom Research and Training Programme 2021-2025
7.
Trans-European Networks for Transport (TEN-T)
8.
Trans-European Networks for Energy (TEN-E)
9. Trans-European Networks for Telecommunications (1)
10.
Connecting Europe Facility
11.
Digital Europe Programme
12.
European Defence Industrial Development Programme
13.
Preparatory Action on Defence Research
14.
European Defence Fund
15.
Act in Support of Ammunition Production (ASAP)
16.
European Defence Industry Reinforcement through common Procurement Act (EDIRPA)
17.
Permanent structured cooperation (PESCO)
18.
European Defence Industry Programme (EDIP)
19.
European Joint Undertaking for ITER
20.
EU4Health Programme
21.
Important Projects of Common European Interest (IPCEI)
22.
Projects of common interest and projects of mutual interest
ANNEX III
TECHNOLOGY AREAS RELEVANT TO RISK ASSESSMENTS PURSUANT TO ARTICLE 19
ANNEX IV
LIST OF CRITICAL MEDICINES
|
ATC level 5 |
ATC description(1) |
Route of administration |
|
|
A - Alimentary tract and metabolism |
|
|
|
A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) |
|
|
A02BC05 |
ESOMEPRAZOLE |
intravenous use |
|
|
A03B - Belladonna and derivatives, plain |
|
|
A03BA01 |
ATROPINE |
intramuscular, intravenous, subcutaneous use |
|
|
A03F - Propulsives |
|
|
A03FA01 |
METOCLOPRAMIDE |
intramuscular, intravenous, subcutaneous use |
|
|
A07A - Intestinal antiinfectives |
|
|
A07AA12 |
FIDAXOMICIN |
oral use |
|
|
A07B - Intestinal adsorbents |
|
|
A07BA01 |
MEDICINAL CHARCOAL |
oral use |
|
|
A10A - Insulins and analogues |
|
|
A10AB01 |
INSULIN HUMAN (fast-acting) |
intramuscular, intravenous, subcutaneous use |
|
A10AB05 |
INSULIN ASPART |
intravenous, subcutaneous use |
|
A10AC01 |
INSULIN HUMAN (intermediate-acting) |
intramuscular, intravenous, subcutaneous use |
|
A10AD01 |
INSULIN HUMAN (intermediate - or long-acting combined with fast-acting) |
intramuscular, intravenous, subcutaneous use |
|
A10AE06 |
INSULIN DEGLUDEC |
subcutaneous use |
|
|
A12C - Other mineral supplements |
|
|
A12CC02 |
MAGNESIUM SULFATE |
intravenous, intramuscular use |
|
|
A16A - Other alimentary tract and metabolism products |
|
|
A16AB02 |
IMIGLUCERASE |
intravenous use |
|
|
B - Blood and blood forming organs |
|
|
|
B01A - Antithrombotic agents |
|
|
B01AA03 |
WARFARIN |
oral use |
|
B01AB01 |
HEPARIN |
haemodialysis, intraarterial, intravenous, subcutaneous use |
|
B01AB02 |
ANTITHROMBIN III |
intravenous use |
|
B01AC04 |
CLOPIDOGREL |
oral use |
|
B01AC16 |
EPTIFIBATIDE |
intravenous use |
|
B01AD02 |
ALTEPLASE |
intravenous use |
|
B01AD11 |
TENECTEPLASE |
intravenous use |
|
B01AE07 |
DABIGATRAN |
oral use |
|
|
B02A - Antifibrinolytics |
|
|
B02AA02 |
TRANEXAMIC ACID |
oral, intravenous use |
|
|
B02B - Vitamin K and other hemostatics |
|
|
B02BA01 |
PHYTOMENADIONE |
intramuscular, intravenous, oral use |
|
B02BB01 |
HUMAN FIBRINOGEN |
intravenous use |
|
B02BD01 |
HUMAN PROTHROMBIN COMPLEX |
intravenous use |
|
B02BD02 |
HUMAN COAGULATION FACTOR VIII |
intravenous use |
|
B02BD03 |
FACTOR VIII INHIBITOR BYPASSING ACTIVITY |
intravenous use |
|
B02BD04 |
HUMAN COAGULATION FACTOR IX |
intravenous use |
|
B02BD05 |
HUMAN COAGULATION FACTOR VII |
intravenous use |
|
B02BD07 |
HUMAN COAGULATION FACTOR XIII |
intravenous use |
|
B02BD08 |
EPTACOG ALFA |
intravenous use |
|
|
B03B - Vitamin B12 and folic acid |
|
|
B03BA03 |
HYDROXOCOBALAMIN |
intravenous, intramuscular, subcutaneous, oral use |
|
|
B05A - Blood and related products |
|
|
B05AA01 |
ALBUMIN |
intravenous use |
|
B05AA02 |
PLASMA PROTEIN FRACTION |
intravenous use |
|
|
B05B - IV solutions |
|
|
B05BB01 |
POTASSIUM CHLORIDE |
intravenous use |
|
B05BC01 |
MANNITOL |
intravenous use |
|
|
B05X - IV solution additives |
|
|
B05XA01 |
POTASSIUM CHLORIDE |
intravenous use |
|
B05XA05 |
MAGNESIUM SULFATE |
intravenous use |
|
|
B06A - Other hematological agents |
|
|
B06AB01 |
HUMAN HEMIN |
intravenous use |
|
B06AC01 |
COMPLEMENT C1 ESTERASE INHIBITOR |
intravenous, subcutaneous use |
|
|
C - Cardiovascular system |
|
|
|
C01A - Cardiac glycosides |
|
|
C01AA05 |
DIGOXIN |
oral, intravenous use |
|
|
C01B - Antiarrhythmics, class I and III |
|
|
C01BB01 |
LIDOCAINE |
parenteral use |
|
C01BB02 |
MEXILETINE |
oral use |
|
C01BC04 |
FLECAINIDE |
oral use |
|
C01BD01 |
AMIODARONE |
intravenous use |
|
|
C01C - Cardiac stimulants excl cardiac glycosides |
|
|
C01CA02 |
ISOPRENALINE |
intravenous use |
|
C01CA03 |
NOREPINEPHRINE |
intravenous use |
|
C01CA04 |
DOPAMINE |
intravenous use |
|
C01CA07 |
DOBUTAMINE |
intravenous use |
|
C01CA24 |
EPINEPHRINE |
endotracheopulmonary, intracardiac, intraosseous, intramuscular, intravenous, subcutaneous use |
|
C01CA26 |
EPHEDRINE |
intravenous, intramuscular, subcutaneous use |
|
C01CE02 |
MILRINONE |
intravenous use |
|
|
C01D - Vasodilators used in cardiac diseases |
|
|
C01DA02 |
GLYCERYL TRINITRATE |
intravenous, sublingual use |
|
|
C01E - Other cardiac preparations |
|
|
C01EB10 |
ADENOSINE |
intravenous use |
|
|
C02A - Antiadrenergic agents, centrally acting |
|
|
C02AB01 |
METHYLDOPA (levorotatory) |
oral use |
|
C02AB02 |
METHYLDOPA (racemic) |
oral use |
|
C02AC01 |
CLONIDINE |
intramuscular, intravenous, subcutaneous, oral use |
|
|
C02D - Arteriolar smooth muscle, agents acting on |
|
|
C02DD01 |
SODIUM NITROPRUSSIDE |
intravenous use |
|
|
C03C - High-ceiling diuretics |
|
|
C03CA01 |
FUROSEMIDE |
intravenous, intramuscular use |
|
|
C07A - Beta blocking agents |
|
|
C07AA05 |
PROPRANOLOL |
oral use |
|
C07AG01 |
LABETALOL |
intravenous use |
|
|
C08C - Selective calcium channel blockers with mainly vascular effects |
|
|
C08CA06 |
NIMODIPINE |
intravenous, intracisternal use |
|
|
C08D - Selective calcium channel blockers with direct cardiac effects |
|
|
C08DA01 |
VERAPAMIL |
intravenous use |
|
|
G - Genito urinary system and sex hormones |
|
|
|
G02A - Uterotonics |
|
|
G02AB01 |
METHYLERGOMETRINE |
intramuscular, intrauterine, intravenous, subcutaneous use |
|
|
G03X - Other sex hormones and modulators of the genital system |
|
|
G03XB01 |
MIFEPRISTONE |
oral use |
|
|
H - Systemic hormonal preparations, excl sex hormones and insulins |
|
|
|
H01B - Posterior pituitary lobe hormones |
|
|
H01BA01 |
ARGIPRESSIN |
intramuscular, intravenous, subcutaneous use |
|
H01BA02 |
DESMOPRESSIN |
intramuscular, intravenous, subcutaneous use |
|
H01BB02 |
OXYTOCIN |
intramuscular, intravenous use |
|
H01BB03 |
CARBETOCIN |
intramuscular, intravenous use |
|
|
H02A - Corticosteroids for systemic use, plain |
|
|
H02AA02 |
FLUDROCORTISONE |
oral use |
|
H02AB04 |
METHYLPREDNISOLONE |
intraarticular, intrabursal, intradermal, intralesional, intramuscular, intravenous, periarticular, rectal use |
|
H02AB06 |
PREDNISOLONE |
oral use |
|
H02AB09 |
HYDROCORTISONE |
intraarticular, intramuscular, intravenous, oral use |
|
|
H03B - Antithyroid preparations |
|
|
H03BA02 |
PROPYLTHIOURACIL |
oral use |
|
H03BB01 |
CARBIMAZOLE |
oral use |
|
H03BB02 |
THIAMAZOLE |
oral use |
|
|
H04A - Glycogenolytic hormones |
|
|
H04AA01 |
GLUCAGON |
intramuscular, intravenous, nasal, subcutaneous use |
|
|
J - Antiinfectives for systemic use |
|
|
|
J01A - Tetracyclines |
|
|
J01AA02 |
DOXYCYCLINE |
oral use |
|
|
J01C - Beta-lactam antibacterials, penicillins |
|
|
J01CA01 |
AMPICILLIN |
intramuscular, intravenous use |
|
J01CA04 |
AMOXICILLIN |
oral, intravenous, intramuscular use |
|
J01CE01 |
BENZYLPENICILLIN |
intraarticular, intramuscular, intrapleural, intrathecal, intravenous use |
|
J01CE02 |
PHENOXYMETHYLPENICILLIN |
oral use |
|
J01CE08 |
BENZATHINE BENZYLPENICILLIN |
intramuscular use |
|
J01CF02 |
CLOXACILLIN |
intravenous, intramuscular use |
|
J01CF05 |
FLUCLOXACILLIN |
inhalation, intraarticular, intramuscular, intrapleural, intravenous, oral use |
|
J01CR02 |
AMOXICILLIN, CLAVULANIC ACID |
oral, intravenous use |
|
J01CR05 |
PIPERACILLIN, TAZOBACTAM |
intravenous use |
|
|
J01D - Other beta-lactam antibacterials |
|
|
J01DC02 |
CEFUROXIME |
oral use |
|
J01DD01 |
CEFOTAXIME |
intramuscular, intravenous use |
|
J01DD02 |
CEFTAZIDIME |
intramuscular, intravenous use |
|
J01DD04 |
CEFTRIAXONE |
intramuscular, intravenous, subcutaneous use |
|
J01DD08 |
CEFIXIME |
oral use |
|
J01DD52 |
CEFTAZIDIME, AVIBACTAM |
intravenous use |
|
J01DF01 |
AZTREONAM |
intramuscular, intravenous use |
|
J01DH56 |
CILASTATIN SODIUM, IMIPENEM, RELEBACTAM |
intravenous use |
|
J01DI54 |
TAZOBACTAM, CEFTOLOZANE |
intravenous use |
|
|
J01E - Sulfonamides and trimethoprim |
|
|
J01EA01 |
TRIMETHOPRIM |
oral use |
|
J01EE01 |
CO-TRIMOXAZOLE |
oral, intravenous use |
|
|
J01F - Macrolides, lincosamides and streptogramins |
|
|
J01FA01 |
ERYTHROMYCIN |
intravenous use |
|
J01FA09 |
CLARITHROMYCIN |
intravenous use |
|
J01FA10 |
AZITHROMYCIN |
intravenous, oral use |
|
J01FF01 |
CLINDAMYCIN |
intramuscular, intravenous use |
|
|
J01G - Aminoglycoside antibacterials |
|
|
J01GB01 |
TOBRAMYCIN |
inhalation, intramuscular, intravenous use |
|
J01GB03 |
GENTAMICIN |
intramuscular, intravenous, subconjunctival use |
|
J01GB06 |
AMIKACIN |
intramuscular, intravenous use |
|
|
J01M - Quinolone antibacterials |
|
|
J01MA02 |
CIPROFLOXACIN |
intravenous use |
|
J01MA12 |
LEVOFLOXACIN |
intravenous use |
|
|
J01X - Other antibacterials |
|
|
J01XA01 |
VANCOMYCIN |
intraperitoneal, intravenous, oral use |
|
J01XA02 |
TEICOPLANIN |
intramuscular, intravenous use |
|
J01XB01 |
COLISTIN |
inhalation, intrathecal, intravenous use |
|
J01XD01 |
METRONIDAZOLE |
intravenous use |
|
J01XX01 |
FOSFOMYCIN |
intravenous use |
|
|
J02A - Antimycotics for systemic use |
|
|
J02AA01 |
AMPHOTERICIN B |
intravenous use |
|
J02AC01 |
FLUCONAZOLE |
intravenous use |
|
J02AC04 |
POSACONAZOLE |
intravenous use |
|
J02AC05 |
ISAVUCONAZOLE |
intravenous, oral use |
|
|
J04A - Drugs for treatment of tuberculosis |
|
|
J04AB02 |
RIFAMPICIN |
oral use |
|
J04AB04 |
RIFABUTIN |
oral use |
|
J04AC01 |
ISONIAZID |
oral use |
|
J04AK01 |
PYRAZINAMIDE |
oral use |
|
J04AK02 |
ETHAMBUTOL |
oral use |
|
J04AK05 |
BEDAQUILINE |
oral use |
|
J04AM02 |
ISONIAZID, RIFAMPICIN |
oral use |
|
|
J04B - Drugs for treatment of lepra |
|
|
J04BA02 |
DAPSONE |
oral use |
|
|
J05A - Direct acting antivirals |
|
|
J05AB01 |
ACICLOVIR |
intravenous use |
|
J05AB06 |
GANCICLOVIR |
intravenous use |
|
J05AB14 |
VALGANCICLOVIR |
oral use |
|
J05AD01 |
FOSCARNET |
intravenous use |
|
J05AF01 |
ZIDOVUDINE |
intravenous, oral use |
|
J05AF05 |
LAMIVUDINE |
oral use |
|
J05AF06 |
ABACAVIR |
oral use |
|
J05AF09 |
EMTRICITABINE |
oral use |
|
J05AG01 |
NEVIRAPINE |
oral use |
|
J05AR02 |
ABACAVIR, LAMIVUDINE |
oral use |
|
|
J06B - Immunoglobulins |
|
|
J06BA01 |
HUMAN NORMAL IMMUNOGLOBULIN |
intravenous, subcutaneous use |
|
J06BA02 |
HUMAN NORMAL IMMUNOGLOBULIN |
intravenous use |
|
J06BB01 |
HUMAN ANTI-D IMMUNOGLOBULIN |
intramuscular, intravenous use |
|
J06BB02 |
HUMAN TETANUS IMMUNOGLOBULIN |
intramuscular, subcutaneous use |
|
J06BB04 |
HUMAN HEPATITIS B IMMUNOGLOBULIN |
intramuscular, intravenous, subcutaneous use |
|
J06BB05 |
HUMAN RABIES IMMUNOGLOBULIN |
intramuscular use |
|
|
J07A - Bacterial vaccines |
|
|
J07AE01 |
CHOLERA VACCINE (inactivated) |
oral use |
|
J07AH07 |
MENINGOCOCCAL GROUP C VACCINE |
intramuscular use |
|
J07AH09 |
MENINGOCOCCAL GROUP B VACCINE |
intramuscular use |
|
J07AJ51 |
DIPHTHERIA, TETANUS, PERTUSSIS VACCINE (inactivated, whole cell) |
intramuscular, subcutaneous use |
|
J07AJ52 |
DIPHTHERIA, TETANUS, PERTUSSIS VACCINE (purified antigen) |
intramuscular, subcutaneous use |
|
J07AM51 |
DIPHTHERIA, TETANUS VACCINE |
intramuscular, subcutaneous use |
|
J07AP03 |
TYPHOID VACCINE (polysaccharide) |
intramuscular, subcutaneous use |
|
|
J07B - Viral vaccines |
|
|
J07BA02 |
ENCEPHALITIS (Japanese, whole virus, inactivated) |
intramuscular use |
|
J07BB01 |
INFLUENZA VACCINE (various forms, strains) |
intramuscular use |
|
J07BB02 |
INFLUENZA VACCINE (various forms, strains) |
intramuscular, subcutaneous use |
|
J07BC01 |
HEPATITIS B VACCINE |
intramuscular, subcutaneous use |
|
J07BC02 |
HEPATITIS A VACCINE |
intramuscular, subcutaneous use |
|
J07BC20 |
HEPATITIS A AND B VACCINE |
intramuscular, subcutaneous use |
|
J07BD52 |
MEASLES, MUMPS, RUBELLA VACCINE |
intramuscular, subcutaneous use |
|
J07BD54 |
MEASLES, MUMPS, RUBELLA, VARICELLA VACCINE |
intramuscular, subcutaneous use |
|
J07BF03 |
POLIOMYELITIS VACCINE (trivalent) |
intramuscular, subcutaneous use |
|
J07BG01 |
RABIES VACCINE |
intradermal, intramuscular, subcutaneous use |
|
J07BH02 |
ROTAVIRUS PENTAVALENT VACCINE |
oral use |
|
J07BK01 |
VARICELLA VACCINE (live) |
intramuscular, subcutaneous use |
|
J07BL01 |
YELLOW FEVER VACCINE |
intramuscular, subcutaneous use |
|
J07BM01 |
PAPILLOMAVIRUS VACCINE |
intramuscular use |
|
J07BM02 |
PAPILLOMAVIRUS VACCINE |
intramuscular use |
|
J07BM03 |
HUMAN PAPILLOMAVIRUS VACCINE (9-valent) |
intramuscular use |
|
|
J07C - Bacterial and viral vaccines, combined |
|
|
J07CA01 |
DIPHTHERIA, TETANUS, POLIOMYELITIS VACCINE |
intramuscular, subcutaneous use |
|
J07CA02 |
DIPHTHERIA, TETANUS, PERTUSSIS, POLIOMYELITIS VACCINE |
intramuscular, subcutaneous use |
|
J07CA06 |
DIPHTHERIA, TETANUS, PERTUSSIS VACCINE |
intramuscular, subcutaneous use |
|
J07CA12 |
DIPHTHERIA, TETANUS, PERTUSSIS, POLIOMYELITIS, HEPATITIS B VACCINE |
intramuscular use |
|
|
L - Antineoplastic and immunomodulating agents |
|
|
|
L01A - Antineoplastic agents |
|
|
L01AA01 |
CYCLOPHOSPHAMIDE |
intramuscular, intravenous, oral use |
|
L01AA02 |
CHLORAMBUCIL |
oral use |
|
L01AA03 |
MELPHALAN |
intraarterial, intravenous, oral use |
|
L01AA06 |
IFOSFAMIDE |
intraarterial, intravenous use |
|
L01AB01 |
BUSULFAN |
intravenous, oral, subcutaneous use |
|
L01AB02 |
TREOSULFAN |
intravenous use |
|
L01AC01 |
THIOTEPA |
intramuscular, intrapericardial, intraperitoneal, intrapleural, intravascular, intravenous use |
|
L01AX04 |
DACARBAZINE |
intravenous use |
|
|
L01B - Antimetabolites |
|
|
L01BA01 |
METHOTREXATE |
epidural, intraarterial, intraarticular, intrabursal, intracoronary, intradiscal, intramuscular, intrathecal, intravenous, oral, periarticular, perineural, rectal, retrobulbar, subconjunctival, subcutaneous, transdermal use |
|
L01BB02 |
MERCAPTOPURINE |
oral use |
|
L01BB03 |
TIOGUANINE |
oral use |
|
L01BB05 |
FLUDARABINE |
epidural, intrabursal, intracoronary, intradiscal, intramuscular, intravenous, oral, perineural, retrobulbar use |
|
L01BC01 |
CYTARABINE |
intramuscular, intrathecal, intravenous, subcutaneous use |
|
L01BC02 |
FLUOROURACIL |
intraarterial, intraarticular, intramuscular, intraperitoneal, intrapleural, intravenous use |
|
L01BC05 |
GEMCITABINE |
intravenous use |
|
|
L01C - Plant alkaloids and other natural products |
|
|
L01CA01 |
VINBLASTINE |
epidural, intrabursal, intracoronary, intradiscal, intramuscular, intravenous, perineural, retrobulbar use |
|
L01CA02 |
VINCRISTINE |
epidural, intrabursal, intracoronary, intradiscal, intramuscular, intravenous, perineural, retrobulbar use |
|
L01CB01 |
ETOPOSIDE |
epidural, intrabursal, intracoronary, intradiscal, intramuscular, intravenous, oral, perineural, retrobulbar use |
|
L01CD01 |
PACLITAXEL |
intravenous use |
|
L01CE01 |
TOPOTECAN |
intravenous, oral use |
|
|
L01D - Cytotoxic antibiotics and related substances |
|
|
L01DB01 |
DOXORUBICIN |
intravenous, intravesical use |
|
L01DB02 |
DAUNORUBICIN |
intravenous use |
|
L01DB03 |
EPIRUBICIN |
epidural, intrabursal, intracoronary, intradiscal, intramuscular, intravenous, intravesical, perineural, retrobulbar use |
|
L01DB06 |
IDARUBICIN |
intravenous use |
|
L01DB07 |
MITOXANTRONE |
intrapleural, intravenous use |
|
L01DC01 |
BLEOMYCIN |
intraarterial, intramuscular, intraperitoneal, intrapleural, intratumoral, intravenous, subcutaneous use |
|
L01DC03 |
MITOMYCIN |
intravenous, intravesical use |
|
|
L01E - Protein kinase inhibitors |
|
|
L01EA03 |
NILOTINIB |
oral use |
|
L01EC02 |
DABRAFENIB |
oral use |
|
L01EC03 |
ENCORAFENIB |
oral use |
|
L01EE01 |
TRAMETINIB |
oral use |
|
L01EL01 |
IBRUTINIB |
oral use |
|
|
L01F - Monoclonal antibodies and antibody drug conjugates |
|
|
L01FA03 |
OBINUTUZUMAB |
intravenous use |
|
L01FB01 |
INOTUZUMAB OZOGAMICIN |
intravenous use |
|
L01FC01 |
DARATUMUMAB |
intravenous, subcutaneous use |
|
L01FF01 |
NIVOLUMAB |
intravenous, subcutaneous use |
|
L01FF02 |
PEMBROLIZUMAB |
intravenous use |
|
L01FF03 |
DURVALUMAB |
intravenous use |
|
L01FX02 |
GEMTUZUMAB OZOGAMICIN |
intravenous use |
|
L01FX05 |
BRENTUXIMAB VEDOTIN |
intravenous use |
|
L01FX17 |
SACITUZUMAB GOVITECAN |
intravenous use |
|
|
L01X - Other neoplastic agents |
|
|
L01XA01 |
CISPLATIN |
epidural, intrabursal, intracoronary, intradiscal, intramuscular, intravenous, perineural, retrobulbar use |
|
L01XA02 |
CARBOPLATIN |
epidural, intrabursal, intracoronary, intradiscal, intramuscular, intravenous, perineural, retrobulbar use |
|
L01XA03 |
OXALIPLATIN |
epidural, intrabursal, intracoronary, intradiscal, intramuscular, intravenous, perineural, retrobulbar use |
|
L01XB01 |
PROCARBAZINE |
oral use |
|
L01XF01 |
TRETINOIN |
oral use |
|
L01XJ01 |
VISMODEGIB |
oral use |
|
L01XX05 |
HYDROXYCARBAMIDE |
oral use |
|
L01XX23 |
MITOTANE |
oral use |
|
L01XX24 |
PEGASPARGASE |
intramuscular, intravenous use |
|
|
L02B - Hormone antagonists and related agents |
|
|
L02BA01 |
TAMOXIFEN |
oral use |
|
|
L03A - Immunostimulants |
|
|
L03AB11 |
PEGINTERFERON ALFA-2A |
subcutaneous use |
|
L03AX03 |
BCG VACCINE (various forms) |
intravesical use |
|
L03AX13 |
GLATIRAMER |
intraarticular, intravenous, periarticular, subcutaneous, transdermal use |
|
L03AX16 |
PLERIXAFOR |
subcutaneous use |
|
|
L04A - Immunosuppressants |
|
|
L04AA03 |
ANTILYMPHOCYTE IMMUNOGLOBULIN (horse) |
intravenous use |
|
L04AA04 |
ANTITHYMOCYTE IMMUNOGLOBULIN (rabbit) |
intravenous use |
|
L04AC02 |
BASILIXIMAB |
intravenous use |
|
L04AC03 |
ANAKINRA |
subcutaneous use |
|
L04AD01 |
CICLOSPORIN |
intravenous, oral use |
|
L04AD02 |
TACROLIMUS |
intravenous, oral use |
|
L04AH01 |
SIROLIMUS |
oral use |
|
L04AX02 |
THALIDOMIDE |
oral use |
|
L04AX03 |
METHOTREXATE |
oral use |
|
|
M - Musculo-skeletal system |
|
|
|
M01C - Specific antirheumatic agents |
|
|
M01CC01 |
PENICILLAMINE |
oral use |
|
|
M03A - Muscle relaxants, peripherally acting agents |
|
|
M03AB01 |
SUXAMETHONIUM |
intramuscular, intraosseous, intravenous use |
|
M03AC04 |
ATRACURIUM |
intravenous use |
|
M03AC09 |
ROCURONIUM |
intravenous use |
|
M03AC11 |
CISATRACURIUM |
intravenous use |
|
|
M03C - Muscle relaxants, directly acting agents |
|
|
M03CA01 |
DANTROLENE |
intravenous use |
|
|
N - Nervous system |
|
|
|
N01A - Anesthetics, general |
|
|
N01AH01 |
FENTANYL |
epidural, intramuscular, intravenous use |
|
N01AH03 |
SUFENTANIL |
epidural, intravenous use |
|
N01AH06 |
REMIFENTANIL |
intramuscular, intravenous use |
|
N01AX03 |
KETAMINE |
intramuscular, intravenous use |
|
N01AX10 |
PROPOFOL |
intravenous use |
|
N01AX14 |
ESKETAMINE |
intramuscular, intravenous use |
|
|
N02A - Opioids |
|
|
N02AA01 |
MORPHINE |
epidural, intramuscular, intravenous, subcutaneous use |
|
|
N02B - Other analgesics and antipyretics |
|
|
N02BE01 |
PARACETAMOL |
intravenous use |
|
|
N03A - Antiepileptics |
|
|
N03AA02 |
PHENOBARBITAL |
intramuscular, intravenous, oral use |
|
N03AB02 |
PHENYTOIN |
intramuscular, intravenous, oral use |
|
N03AD01 |
ETHOSUXIMIDE |
oral use |
|
N03AE01 |
CLONAZEPAM |
oral use |
|
N03AF01 |
CARBAMAZEPINE |
oral use |
|
N03AG01 |
VALPROIC ACID |
intravenous, oral use |
|
N03AG04 |
VIGABATRIN |
oral use |
|
|
N04A - Anticholinergic agents |
|
|
N04AA02 |
BIPERIDEN |
intramuscular, intravenous use |
|
|
N05A - Antipsychotics |
|
|
N05AD01 |
HALOPERIDOL |
intraarticular, intramuscular, intravascular, intravenous, oral use |
|
N05AH03 |
OLANZAPINE |
intramuscular use |
|
N05AN01 |
LITHIUM |
oral use |
|
|
N05B - Anxiolytics |
|
|
N05BA01 |
DIAZEPAM |
intramuscular, intravenous, rectal use |
|
N05BA06 |
LORAZEPAM |
intramuscular, intravenous use |
|
|
N05C - Hypnotics and sedatives |
|
|
N05CD08 |
MIDAZOLAM |
intramuscular, intravenous, subcutaneous, rectal use |
|
N05CM18 |
DEXMEDETOMIDINE |
intravenous, subcutaneous use |
|
|
N06A - Antidepressants |
|
|
N06AX27 |
ESKETAMINE |
nasal use |
|
|
N06B - Psychostimulants, agents used for ADHD and nootropics |
|
|
N06BC01 |
CAFFEINE |
intravenous, oral use |
|
|
N07A - Parasympathomimetics |
|
|
N07AA01 |
NEOSTIGMINE |
intramuscular, intravenous, subcutaneous use |
|
|
N07X - Other nervous system drugs |
|
|
N07XX02 |
RILUZOLE |
oral use |
|
|
P - Antiparasitic products, insecticides and repellents |
|
|
|
P01A - Agents against amoebiasis and other protozoal diseases |
|
|
P01AB01 |
METRONIDAZOLE |
intravenous use |
|
|
P01C - Agents against leishmaniasis and trypanosomiasis |
|
|
P01CX01 |
PENTAMIDINE |
inhalation, intramuscular, intravenous use |
|
|
P02C - Antinematodal agents |
|
|
P02CA03 |
ALBENDAZOLE |
oral use |
|
|
R - Respiratory system |
|
|
|
R03A - Adrenergics, inhalants |
|
|
R03AC02 |
SALBUTAMOL |
inhalation, nasal, oral use |
|
|
R03B - Other drugs for obstructive airway diseases, inhalants |
|
|
R03BB01 |
IPRATROPIUM |
inhalation, oral use |
|
|
R03C - Adrenergics for systemic use |
|
|
R03CA02 |
EPHEDRINE |
intramuscular, intravenous, subcutaneous use |
|
R03CC02 |
SALBUTAMOL |
intramuscular, intravenous, subcutaneous use |
|
|
R05C - Expectorants, excl combinations with cough suppressants |
|
|
R05CB01 |
ACETYLCYSTEINE |
intravenous use |
|
R05CB13 |
DORNASE ALFA (DESOXYRIBONUCLEASE) |
inhalation use |
|
|
S - Sensory organs |
|
|
|
S01E - Antiglaucoma preparations and miotics |
|
|
S01EB01 |
PILOCARPINE |
ocular use |
|
S01EB09 |
ACETYLCHOLINE |
intraocular use |
|
S01EC01 |
ACETAZOLAMIDE |
oral use |
|
|
S01F - Mydriatics and cycloplegics |
|
|
S01FA04 |
CYCLOPENTOLATE |
ocular use |
|
|
S01L - Ocular vascular disorder agents |
|
|
S01LA01 |
VERTEPORFIN |
intravenous use |
|
|
S02A - Antiinfectives |
|
|
S02AA15 |
CIPROFLOXACIN |
oral use |
|
|
S03A - Antiinfectives |
|
|
S03AA07 |
CIPROFLOXACIN |
oral use |
|
|
V - Various |
|
|
|
V03A - All other therapeutic products |
|
|
V03AB06 |
SODIUM THIOSULFATE |
intravenous use |
|
V03AB14 |
PROTAMINE |
intravenous use |
|
V03AB15 |
NALOXONE |
intramuscular, intravenous, subcutaneous use |
|
V03AB17 |
METHYLTHIONINIUM |
intravenous use |
|
V03AB23 |
ACETYLCYSTEINE |
intravenous use |
|
V03AB25 |
FLUMAZENIL |
intravenous use |
|
V03AB33 |
HYDROXOCOBALAMIN |
intramuscular, intravenous, oral, subcutaneous use |
|
V03AB34 |
FOMEPIZOLE |
intravenous use |
|
V03AB35 |
SUGAMMADEX |
intravenous use |
|
V03AB37 |
IDARUCIZUMAB |
intravenous use |
|
V03AC01 |
DEFEROXAMINE |
intramuscular, intraperitoneal, intravenous, subcutaneous use |
|
V03AE01 |
POLYSTYRENE SULFONIC ACID |
oral use |
|
V03AF01 |
MESNA |
intravenous, oral use |
|
V03AF02 |
DEXRAZOXANE |
intravenous use |
|
V03AF03 |
FOLINIC ACID |
intramuscular, intravenous use |
|
V03AF07 |
RASBURICASE |
intravenous use |
|
|
V04C - Other diagnostic agents |
|
|
V04CF01 |
TUBERCULIN |
intradermal use |
|
|
V09G - Cardiovascular system |
|
|
V09GA04 |
ALBUMIN (Technetium, 99mTc) |
intravenous use |
|
V09GB02 |
ALBUMIN (Iodine, 125I) |
intradermal, intratumoral, intravenous, subcutaneous use |
|
|
V10X - Other therapeutic radiopharmaceuticals |
|
|
V10XX03 |
RADIUM (223RA) DICHLORIDE |
intravenous use |
|
(1) The Anatomical Therapeutic Chemical (ATC) code: a unique code assigned to a medicine according to the organ or system it works on and how it works. The classification system is maintained by the World Health Organization (WHO). A statement has been made with regard to this Regulation and can be found in OJ C, C/2026/3337, 26.6.2026, ELI: http://data.europa.eu/eli/C/2026/3337/oj. |
||